Šīs tīmekļa vietnes satura kvalitātes uzlabošanai un pielāgošanai lietotāju vajadzībām tiek lietotas sīkdatnes - tai skaitā arī trešo pušu sīkdatnes. Turpinot lietot šo vietni Jūs piekrītat sīkdatņu lietošanai.
Sales of Olainfarm Continue Growing in February
Emitents Olainfarm, AS (213800WCG52W62ENOP27)
Veids 3.1. Papildu regulētā informācija, kas ir jāatklāj saskaņā ar dalībvalsts tiesību aktiem
Valoda EN
Statuss Publicēts
Versija
Datums 2019-03-15 16:44:02
Versijas komentārs
Teksts

Consolidated sales – February and 2 months

Preliminary consolidated results of JSC Olainfarm for February 2019, show that the Group has made sales worth 11.4 million euros, which represents an increase by 7% compared to February of 2018. Preliminary results for two months of this year demonstrate 20% sales increase, as sales during this period reached 23.9 million euros.  Products of Olainfarm Group during this period were sold in 40 countries worldwide.  

According to consolidated sales numbers for February, three major sales markets were Russia, with 15% sales increase, Latvia, with 14% sales increase and Belarus with the sales increase of 3%. Amongst the 10 biggest sales markets, the sales have been shrinking only in Lithuania (by 43%), Kazakhstan (by 37%) and Uzbekistan (by 6%). All other key markets demonstrated sales growth during February, and significant shipments were also made to Japan and Canada. 

In two months of 2019, the main sales markets of Olainfarm Group remained the same: Latvia (27% share), Russia, (26% share), Belarus (15%) and Ukraine (10%).   Other major sales markets include Kazakhstan, Uzbekistan, Germany, The Netherlands, Japan, Canada and Poland.  The most rapid sales growth during this two-month period was achieved in The Netherlands, where sales grew by 190% compared to last year, and Poland, where sale grew by 45%.  Russia has demonstrated 39% sales increase and significant shipments were also made to Canada.  During this period only sales to Uzbekistan have been shrinking (by 7%).

 February 2019, consolidated sales  

Sales, thsnd. EUR

Share in total sales

Changes to February 2018

Russia

3 156

28%

15%

Latvia

3 156

28%

14%

Belarus

1 706

15%

3%

Ukraine

1 173

10%

14%

Japan

336

3%

NA

Canada

323

3%

NA

Uzbekistan

210

2%

-6%

Kazakhstan

189

2%

-37%

Germany

149

1%

4%

Lithuania

130

1%

-43%

Other

913

8%

-42%

Total

11 440

100%

 7%

 

2 months of 2019, consolidated sales

Sales, thsnd. EUR

Share in total sales

Changes to 2 months of 2018

Latvia

 6 553

27%

15%

Russia

6 211

26%

39%

Belarus

3 942

17%

17%

Ukraine

2 681

11%

26%

Germany

394

2%

11%

Uzbekistan

367

2%

-7%

The Netherlands

353

1%

190%

Japan

337

1%

7%

Canada

323

1%

NA

Poland

257

1%

45%

Other

2 443

10%

-15%

Total

23 859

100%

20%

 

Unconsolidated sales – February and 2 months

According to preliminary unconsolidated numbers, sales of JSC Olainfarm in February reached 8.7 million euros, which represents an increase by 23% compared to February of 2018.  Such an increase was mainly influenced by sales increase in Italy (by 420%), Russia (by 85%) and Uzbekistan (by 23%). Sales shrunk in Kazakhstan (by 44%), Germany (by 29%), Latvia (by 7%) and Belarus (by 5%).

Unconsolidated sales results for two months show that sales of JSC Olainfarm reached 18.6 million euros, which represents and increase by 19% compared to two months of 2018.  During the reporting period, sales have increased in all major sales markets of Olainfarm, except Uzbekistan, where sales shrunk by 7%.  In this two-months period, sales of Olainfarm to Turkmenistan grew by 437%, sales to The Netherlands grew by 190, but sales Russia by 41%.

February 2019, unconsolidated sales

Sales, thsnd. EUR

Share in total sales

Changes to February 2018

Russia

2 744

32%

85%

Belarus

1 424

16%

-5%

Latvia

1 397

16%

-7%

Ukraine

1 171

13%

6%

Japan

336

4%

NA

Canada

323

4%

NA

Uzbekistan

210

2%

23%

Germany

146

2%

-29%

Kazakhstan

130

1%

-44%

Italy

127

1%

420%

Other

696

8%

-20%       

Total

8 704

100%

23%

 

2 months of 2019. unconsolidated sales

Sales, thsnd. EUR

Share in total sales

Changes to 2 months of 2018

Russia

5 577

30%

41%

Belarus

3 353

18%

15%

Latvia

3 044

16%

1%

Ukraine

2 679

14%

26%

Germany

391

2%

12%

Uzbekistan

367

2%

-7%

The Netherlands

353

2%

190%

Japan

337

2%

7%

Canada

323

2%

NA

Turkmenistan

251

1%

437%

Other

1 964

11%

-20%

Total

18 638

100%

19%

 

Results of Daughter companies – February and 2 months

Sales of pharmacy chain of SIA Latvijas Aptieka in February 2019 exceeded 2.1 million euros, which represents and increase by 27% compared to February of 2018.  Sales of SIA Silvanols in February reached 0.58 million euros, which is comparable to sales made one year ago.  Combined sales of Tonus Elast and Elast Medical in February 2019 were 0.7 million euros, an increase by 8%, medical centers of Olainmed and Diamed made sales worth 0.24 million, while Belarus daughter company NPK Biotest made sales of 0.28 million euros. 

In 2 months of 2019, SIA Latvijas Aptieka’s sales were 4.5 million euros, demonstrating 21% increase, sales of SIA Silvanols reached 1.1 million euros (an increase by 6%).  Combined sales of Tonus Elast and Elast Medical also grew by 6% to 1.23 million euros.  Medical centers sold services worth 0.47 million, while NPK Biotest’s sales reached 0.55 million

 

 

February 2019

2 months of 2019

Sales markets of Olainfarm

26

35

Sales markets of the Group

32

40

Number of pharmacies

69

 

Sales of Latvijas Aptieka, thsnd.

2 124

4 469

Sales of Medical centers, thsnd.

238

 

470

 

Sales of NPK Biotest, thsnd.

282

547

Sales of Tonus Elast and Elast Medical, thsnd.

704

 

1 233

 

Sales of Silvanols, thsnd.

 580

1 065

 

According to the budgets of JSC Olainfarm, unconsolidated sales of the company in 2019 are planned to reach 99 million euros, while consolidated sales are expected at 133 million euros.  According to these preliminary sales figures, in 2 months of 2019, 19% of annual target for unconsolidated sales and 18% of annual target for consolidated sales are reached.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top -quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:      

Inga Krūkle
Member of the Board JSC Olainfarm
Ph.: +371 28698449
inga.krukle@olainfarm.com

Pielikumi